Podcasts about oncology and hematology

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc As CAR T-cell therapy options expand for relapsed or refractory (R/R) multiple myeloma, comparative data may help clinicians weigh efficacy and safety when selecting treatment. One recent matching-adjusted indirect comparison of anitocabtagene autoleucel and ciltacabtagene autoleucel drew on data from the iMMAGINE-1 and CARTITUDE-1 trials to evaluate response and safety outcomes, including cytokine release syndrome, ICANS, infections, and non-relapse mortality. To learn about the findings, their clinical implications, and important limitations of the analysis, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc A recent analysis used matching-adjusted indirect comparisons to evaluate anitocabtagene autoleucel, teclistamab, and talquetamab for relapsed or refractory (R/R) multiple myeloma, drawing on data from the iMMAGINE-1, MajesTEC-1, and MonumenTAL-1 trials. The analysis compared efficacy and safety outcomes across these CAR T-cell and bispecific therapies, including overall response, depth of response, MRD negativity, cytokine release syndrome, ICANS, infections, and non-relapse mortality. To explore the findings, their potential clinical implications, and key limitations of these indirect comparisons, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM For patients who smoke or have a history of smoking, seeking lung cancer screening can mean confronting more than the fear of a diagnosis; it can also mean anticipating blame and judgment. Dr. Lisa Carter-Bawa joins us to share how tobacco-related stigma and nihilism can discourage screening, honest conversations, and follow-up care. Learn how approaching patients with greater awareness and compassion can help create a more supportive path to early detection. Dr. Carter-Bawa is the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation and a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She spoke about this topic at the 2026 World Conference on Lung Cancer.

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM Even well-intentioned conversations about tobacco use can leave patients feeling judged and potentially less willing to engage in lung cancer screening, follow-up, or cessation support. Tune in as Dr. Lisa Carter-Bawa shares practical strategies for fostering more supportive, patient-centered conversations that reduce stigma and keep the door open to screening and continued care. In addition to being the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery & Innovation, she's also a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She also spoke about this topic at the 2026 World Conference on Lung Cancer.

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM For patients who smoke or have a history of smoking, seeking lung cancer screening can mean confronting more than the fear of a diagnosis; it can also mean anticipating blame and judgment. Dr. Lisa Carter-Bawa joins us to share how tobacco-related stigma and nihilism can discourage screening, honest conversations, and follow-up care. Learn how approaching patients with greater awareness and compassion can help create a more supportive path to early detection. Dr. Carter-Bawa is the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery and Innovation and a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She spoke about this topic at the 2026 World Conference on Lung Cancer.

Guest: Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM Even well-intentioned conversations about tobacco use can leave patients feeling judged and potentially less willing to engage in lung cancer screening, follow-up, or cessation support. Tune in as Dr. Lisa Carter-Bawa shares practical strategies for fostering more supportive, patient-centered conversations that reduce stigma and keep the door open to screening and continued care. In addition to being the Director of the Cancer Prevention Precision Control Institute at the Hackensack Meridian Health Center for Discovery & Innovation, she's also a Co-Leader of the Cancer Prevention and Control Program and the Deputy Associate Director of Community Outreach and Engagement for the Georgetown University Lombardi Comprehensive Cancer Center. She also spoke about this topic at the 2026 World Conference on Lung Cancer.

Guest: Jonathon B. Cohen, MD, MS As chemotherapy-free approaches for mantle cell lymphoma continue to evolve, important questions remain about how best to incorporate them into clinical practice. Here to help shed light on the key unknowns surrounding patient selection, treatment sequencing, and the potential implications of using targeted and immune therapies in the frontline setting is Dr. Jonathon Cohen. He's a board-certified hematologist and medical oncologist at Emory Winship Cancer Institute in Atlanta, and he spoke about this topic at the 2026 Society of Hematologic Oncology Annual Meeting.

Guest: Jonathon B. Cohen, MD, MS As chemotherapy-free approaches for mantle cell lymphoma continue to evolve, important questions remain about how best to incorporate them into clinical practice. Here to help shed light on the key unknowns surrounding patient selection, treatment sequencing, and the potential implications of using targeted and immune therapies in the frontline setting is Dr. Jonathon Cohen. He's a board-certified hematologist and medical oncologist at Emory Winship Cancer Institute in Atlanta, and he spoke about this topic at the 2026 Society of Hematologic Oncology Annual Meeting.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is bringing together leaders, emerging investigators, and educational opportunities from across the lung cancer field. Dr. Triparna Sen sat down with us to share her perspective on how early-career clinicians and researchers can get the most out of their WCLC experience. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD The 2026 World Conference on Lung Cancer (WCLC) is set to spotlight pivotal research that could inform the next chapter of lung cancer care. Dr. Triparna Sen previews key phase III trials across small cell and non-small cell lung cancer, including emerging data on antibody-drug conjugates, targeted therapies, MRI surveillance, and adjuvant treatment, as well as sessions focused on biomarkers and liquid biopsy. Dr. Sen is the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Guest: Triparna Sen, PhD How does the immune microenvironment change as EGFR-mutant lung adenocarcinoma develops treatment resistance and undergoes histologic transformation? In a recent study, multiomic spatial findings revealed broad immune suppression following transformation, including changes in T cells and immunosuppressive macrophages. Learn more with Dr. Triparna Sen, who shared these new findings at the 2026 World Conference on Lung Cancer. She's the Max Morehouse Endowed Chair in Cancer Research and Associate Director of Research for the Division of Medical Oncology at The Ohio State University, as well as the Director of the Lung Cancer Preclinical Therapeutics Platform at The Ohio State University Comprehensive Cancer Center.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Chul Hyun, MD, PhD, MPH Gastric cancer risk in the United States varies substantially across populations, yet prevention remains largely based on symptoms. Join Dr. Peter Buch and Dr. Chul Hyun, Director of the Gastric Cancer Prevention and Screening Program at the Yale School of Medicine, as they explore how recognizing key risk factors may help us identify patients who warrant closer evaluation.

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-survival-ceiling-in-es-sclc-why-checkpoint-blockade-alone-is-not-enough/60948/ This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/rationale-of-emerging-antigen-directed-strategies-in-frontline-es-sclc/60949/ This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-emerging-antigen-directed-strategies-in-es-sclc/60950/ This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/on-the-horizon-emerging-antigen-directed-strategies-across-disease-stage/60951/ This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including novel antibody combinations, bispecific T-cell engagers, and antibody-drug conjugates. Faculty discuss emerging clinical evidence for investigational approaches across both extensive-stage and limited-stage disease settings. Emphasis is placed on how disease stage, prior treatment exposure, mechanism of action, and evolving trial data can inform treatment selection, clinical trial referral, and future integration of antigen-directed therapies into SCLC care.

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-research-into-practice-in-breast-cancer-emerging-data-and-the-expanding-role-of-adcs/57226/ The role of antibody-drug conjugate (ADC) therapy has been well established in metastatic breast cancer. Recent phase 3 data have provided evidence for expanded indications for early breast cancer and triple-negative breast cancer (TNBC), leading to updates in current treatment guidelines. In this case-based activity, Drs. Tiffany Traina and Sara Hurvitz explore the supporting data for use of ADCs in the neoadjuvant, post-neoadjuvant, and metastatic TBNC settings.=

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-case-for-change-why-perioperative-immunotherapy-matters-in-la-hnscc/60852/ This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-evidence-base-key-trials-and-emerging-data/60853/ This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/building-the-team-integrating-immunotherapy-into-multidisciplinary-care/60854/ This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-data-to-decision-patient-selection-and-real-world-application/60855/ This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-abstract-to-action-in-breast-cancer-interpreting-recent-data-on-oral-serds-and-endocrine-targeting-strategies/57230/ Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/cracking-the-code-risk-stratification-guidelines-to-identify-high-risk-patients/57192/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-timing-therapies-that-change-outcomes/57193/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/adt-intensification-in-biochemically-recurrent-prostate-cancer-when-to-act/57194/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-in-practicebringing-targeted-therapy-to-mhspc/57201/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Guest: Howard Fine, M.D. Dr. Howard Fine, a neuro-oncologist at NewYork-Presbyterian and Weill Cornell Medicine, discusses how a new approach to glioblastoma research may expand treatment options and advance precision oncology. His preclinical model, GLICO, uses cerebral organoids, or mini brains, to create a more accurate representation of glioblastoma tumor biology. Through an advanced, high-throughput drug-screening system that Dr. Fine and his team developed, they can screen hundreds of GLICOs against various drug regimens to identify personalized glioblastoma therapies—with the ultimate goal of extending patient survival for one of the most lethal cancers. © 2026 NewYork-Presbyterian

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-on-trop2-directed-adcs-into-global-practice-in-metastatic-tnbc/60637/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-first-line-treatment-of-metastatic-tnbc/60636/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-trop2-directed-adcs-in-metastatic-tnbc/60635/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-first-line-treatment-in-metastatic-tnbc-ineligible-for-immunotherapy/60634/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/comparing-first-line-trop2-directed-adcs-in-metastatic-tnbc-latest-clinical-evidence/60633/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

CME credits: 1.00 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/managing-egfr-mutated-mnsclc-data-recommendations/56306/ Over the past two decades, advances in disease biology and precision medicine have transformed the diagnosis and treatment of non–small cell lung cancer (NSCLC). Improved understanding of NSCLC molecular drivers has led to the development of targeted therapies and immunotherapies that have enhanced disease control, symptom management, and survival for selected patients. The treatment landscape for EGFR-mutated NSCLC continues to evolve rapidly, with therapies increasingly guided by molecular profiling and histology. As treatment options expand and become more complex, members of the oncology team must stay current on molecular testing, emerging therapies, and toxicity management to optimize patient outcomes.=

CME credits: 0.75 Valid until: 16-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-first-line-treatment-of-metastatic-tnbc/60632/ This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for immunotherapy. Faculty discuss how efficacy, safety profiles, dosing considerations, and patient-specific factors influence treatment selection and sequencing. Practical guidance on adverse event monitoring and mitigation supports personalized and evidence-based care. The activity also explores future directions for TROP2-directed ADCs in both metastatic and early-stage TNBC settings.

Host: Steve Jackson, PharmD Guest: Jahan Aghalar, MD Guest: Ulka Vaishampayan, MD With more treatment options than ever for metastatic castration-sensitive prostate cancer (mCSPC), applying clinical trial data in everyday practice has become increasingly complex. Understanding how differences in trial design, patient populations, and clinical endpoints influence treatment decisions is essential for delivering personalized care. Join Dr. Steve Jackson as he speaks with Drs. Jahan Aghalar and Ulka Vaishampayan about practical approaches to interpreting the evidence and tailoring therapy to the patients in front of you. Dr. Aghalar is an Adjunct Assistant Professor at NYU Grossman Long Island School of Medicine, and Dr. Viashampayan is a Professor of Internal Medicine at the University of Michigan Medical School in Ann Arbor, the Director of the Phase One Program, and co-founder of the Translational and Clinical Research Program at the Rogel Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bilal Siddiqui, MD Long-term management of metastatic castration-sensitive prostate cancer (mCSPC) goes beyond selecting an effective therapy—it also requires careful consideration of tolerability, drug interactions, and treatment access. Balancing these factors can help clinicians personalize care while supporting adherence and quality of life over time. Joining Dr. Charles Turck to share practical strategies for navigating these decisions and tailoring treatment to each patient's unique needs is Dr. Bilal Siddiqui. He's an Assistant Professor in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.

CME credits: 1.00 Valid until: 07-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-through-the-continuum-applying-biomarker-guided-therapies-in-ovarian-cancer/56953/ This chapterized online educational activity is designed to translate biomarker-driven evidence into practical decision-making across the ovarian cancer continuum. Through expert discussion, participants will apply biomarker insights to guide treatment strategies in both frontline maintenance and platinum-resistant settings. Faculty emphasize patient selection, sequencing strategies, and interpretation of clinical data within real-world practice constraints. The program also highlights proactive approaches to identifying and managing treatment-related adverse events to support adherence and quality of life. This activity equips clinicians with practical tools to integrate biomarker findings, clinical evidence, and patient-centered considerations into individualized ovarian cancer care. =

Host: Alexandria May, PharmD, BCPS Guest: Neil M. Iyengar, MD As first-line treatment options for metastatic triple-negative breast cancer continue to expand, emerging evidence and guideline updates are reshaping treatment selection. In this expert-led discussion, Dr. Alexandria May and Dr. Neil Iyengar review the growing role of biomarker-driven decision-making and examine how data from ASCENT-03, ASCENT-04, and TROPION-Breast02 are influencing preferred treatment approaches. Dr. Iyengar is the Director of the Cancer Survivorship Program and Co-Director of the Breast Medical Oncology Program at Winship Cancer Institute at Emory University.

CME credits: 0.25 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-mCSPC-Molecular-Profiling-and-Biomarker-Directed-Therapies/56688/ This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration-sensitive prostate cancer (mCSPC). Drs. Neeraj Agarwal and Rana McKay discuss the clinical significance of PTEN loss and other genomic alterations, their prognostic implications, and how they may inform treatment selection. The conversation reviews emerging data on targeted therapeutic strategies and the integration of precision medicine earlier in the disease course. Practical considerations for incorporating biomarker assessment into clinical decision-making are also examined. =

CME credits: 0.25 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Cracking-the-Code-in-Localized-nmCSPC-Risk-Treatment-and-Timing/56686/ In this podcast, Drs. Rana McKay and Neeraj Agarwal discuss risk stratification in localized and nonmetastatic castration-sensitive prostate cancer (CSPC), highlighting the clinical and imaging factors used to identify patients at increased risk of recurrence and disease progression. The faculty examine the evolving role of treatment intensification, including androgen deprivation therapy–based combination approaches and the earlier use of androgen receptor pathway inhibitors in patients with high-risk disease. They also explore how advances in imaging, multidisciplinary care, and emerging clinical evidence are shaping treatment selection and timing. In addition, the discussion addresses practical considerations for managing adverse events associated with intensified therapy and incorporating these strategies into clinical practice. =

Guest: Urs Weber, MD As outcomes improve for patients with ALK+ non-small cell lung cancer, attention is shifting toward therapies designed to push disease control even further. Tune in as Dr. Urs Weber examines promising agents in development and discusses the momentum driving the next phase of ALK-targeted treatment. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

Guest: Urs Weber, MD Advances in targeted therapies have dramatically improved outcomes for patients with ALK-positive non-small cell lung cancer, but new resistance challenges continue to emerge. In this episode, Dr. Urs Weber discusses how cancers adapt to treatment, why off-target resistance and histologic transformation are becoming increasingly important, and where future research may help close critical gaps in care. Dr. Weber is an Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus.

Guest: Urs Weber, MD For patients with ALK-positive non-small cell lung cancer, staying on therapy often means staying ahead of treatment-related toxicities. Join Dr. Urs Weber, Assistant Professor in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus, as he explores practical strategies for toxicity management, dose optimization, and shared decision-making to help support durable outcomes.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Targeting-PTEN-Why-It-Matters/57200/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Winning-the-Battle-Against-Side-Effects-Adverse-Event-Management-in-HSPC/57198/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/Case-Implementing-ADT-Intensification-in-mHSPC/57197/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

CME credits: 1.00 Valid until: 16-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/De-Novo-mHSPC-Recognizing-the-Patients-Who-Need-More/57195/ This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy. *Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.